Table 5

Overview of TEAEs

Disease status: CRP requirement (mg/dL): n:	Idiopathic			PPS		Total
Disease status: CRP requirement (mg/dL): n:	Active* >1 12	Active† ≤1 3	CS-dep‡ N/A 6	Active§ >1 1	CS-dep¶ N/A 3	All*†‡§¶ N/A 25
Patients with ≥1 TEAE, n (%)	12 (100.0)	3 (100.0)	6 (100.0)	1 (100.0)	3 (100.0)	25 (100.0)
Patients with ≥1 treatment-related TEAE, n (%)	9 (75.0)	2 (66.7)	3 (50.0)	1 (100.0)	2 (66.7)	17 (68.0)
Patients with ≥1 serious TEAE, n (%)	2 (16.7)	0	0	0	0	2 (8.0)
Patients with ≥1 treatment-related serious TEAE, n (%)	1 (8.3)	0	0	0	0	1 (4.0)
Patients with ≥1 TEAE leading to discontinuation, n (%)	1 (8.3)	0	0	0	0	1 (4.0)
Patients with ≥1 TEAE leading to death, n (%)	0	0	0	0	0	0
Patients with TEAEs by severity, n (%)
Mild	9 (75.0)	3 (100.0)	4 (66.7)	1 (100.0)	2 (66.7)	19 (76.0)
Moderate	2 (16.7)	0	2 (33.3)	0	0	4 (16.0)
Severe	1 (8.3)	0	0	0	1 (33.3)	2 (8.0)

*Part 1.
†Part 2.
‡Part 3.
§Part 4.
¶Part 5.
CRP, C reactive protein; CS-dep, corticosteroid dependent; PPS, postpericardiotomy syndrome; TEAEs, treatment-emergent adverse events.